All News

The vastly improved outlook for patients with chronic lymphocytic leukemia (CLL) was named the American Society of Clinical Oncology's inaugural "Cancer Advance of the Year."

Last week, I walked the massive halls of Moscone West in San Francisco and attended the Gastrointestinal Cancers Symposium, better known as ASCO GI. It is a meeting I always feel quite privileged to attend; it offers a glimpse into the work, passion, and expertise that goes into the many aspects of being able to live with metastatic colon cancer.

Those of us living with metastatic cancer ride a see-saw between hope and acceptance.

Changing the administration schedule for Gemzar (gemcitabine) plus Abraxane (nab-paclitaxel) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.

An analysis of the phase 3 NAPOLI-1 trial supports the benefits of adding MM-398 chemotherapy for the treatment of patients with metastatic pancreatic cancer who were previously treated with Gemzar.

The stress of cancer doesn't leave us at bedtime. Focusing on relaxation, rather than sleep, can get you the healing rest you need.

Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.

It's taken me a while to accept that it's OK to not be OK. Sometimes the only way to keep moving forward is to stop and have a pity party first.

Among patients with metastatic gastric cancer treated with the PD-1 inhibitor Keytruda, the agent showed promising activity, according to updated findings from the KEYNOTE-012 study presented at the Gastrointestinal Cancers Symposium.

In the past four months, the PD-1 inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) have been approved for the treatment of advanced melanoma. Jeffery S. Weber, a senior member at Moffitt Cancer Center in Tampa, Fla., provides insight on what this means for treating patients.

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

Patients with metastatic colorectal cancer treated with Cyramza and standard FOLFIRI lived a median of 1.6 months longer than patients treated with FOLFIRI alone, according to results from the phase 3 RAISE trial.

Intensifying the chemotherapy component of a standard regimen containing Avastin reduced the risk of death and increased five-year overall survival in newly diagnosed metastatic colorectal cancer.

Being diagnosed with cancer feels kind of like having a stranger barge into your home, throw everything you care about out the window, shut off the power and heat, then lock you inside … times 100.

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of eight months longer and experienced greater disease-free survival after their cancer treatment, according to research reported at the 2015 Gastrointestinal Cancers Symposium.

A "watch and wait" surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery, according to a retrospective review of clinical data presented at the 2015 Gastrointestinal Cancers Symposium.

A phase 3 trial of Opdivo (nivolumab) in patients with non-small cell lung cancer was stopped early after results determined that the drug improves survival.

Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.

A Food and Drug Administration advisory committee unanimously recommended approval of EP2006, a biosimilar version of Neupogen (filgrastim).

Men undergoing prostate cancer treatment should give special attention to ensuring good pelvic floor strength in order to reduce side effects of treatment and maximize urinary and sexual function.

January is National Blood Donors Month. Some survivors are eligible to roll up a sleeve and give fellow cancer patients the ultimate gift.

Lauren Hill, a college basketball player diagnosed with a rare childhood brain tumor, brought attention to the disease and raised more than $1 million for DIPG research. Hill passed away on April 10.

American Cancer Society's annual report shows 1.5 million deaths averted over the past two decades, as well as a jump in survivorship numbers.

As a lung cancer researcher and medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Wash., Howard L. "Jack" West has made communicating with oncology specialists and patients part of his professional mission.

Caregivers walk alongside cancer patients through every step of the journey.

A spouse describes his wife's arrival in Cancerland

When was your last truly remarkable New Year's Eve?

It's hard to believe that 2014 is but a memory. What a unique year to have experienced....filled with the

One-third of men over 70 years of age who undergo radical prostatectomy for prostate cancer and then experience biochemical recurrence have no need for salvage treatment, according to a recent study.

The FDA has updated the label for Gazyva (obinutuzumab) plus chlorambucil to include data from stage 2 of the phase 3 CLL11 study, which detailed an improvement in progression-free survival as a frontline treatment for patients with chronic lymphocytic leukemia.